Detalles de la búsqueda
1.
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Nature
; 623(7989): 1053-1061, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37844613
2.
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Lancet Oncol
; 21(11): 1478-1488, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33128873
3.
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.
Clin Cancer Res
; 28(21): 4634-4641, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35984704
4.
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.
J Immunother Cancer
; 10(6)2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35717027
5.
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.
Cancer Discov
; 11(1): 92-107, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32958578
6.
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Cancer Discov
; 10(10): 1528-1543, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32532747
Resultados
1 -
6
de 6
1
Próxima >
>>